Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 4
2004 10
2005 7
2006 5
2007 7
2008 4
2009 5
2010 4
2011 4
2012 5
2013 2
2014 3
2015 4
2016 5
2017 4
2018 3
2019 5
2020 3
2021 7
2022 8
2023 7
2024 3
2025 9
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Sanyal AJ, et al. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. N Engl J Med. 2025. PMID: 40305708 Clinical Trial.
Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
Akuta N, Kogiso T, Ikejima K, Otsuka M, Kawaguchi T, Kawanaka M, Takahashi H, Tamaki N, Nakagawa H, Hikita H, Fujii H, Yamaguchi K, Yoneda M, Kon K, Uchiyama A, Seko Y, Sakane S, Shigefuku R, Fujiwara N, Iwaki M, Kobayashi T, Adachi T, Takeuchi Y, Tsutsumi T, Nakano D, Shibayama K, Urata N, Miyaaki H, Kuroda H, Koseki M, Sone H, Matsubayashi Y, Kakisaka K, Takai A, Notsumata K, Seike M, Takei Y, Takeyama Y, Eguchi S, Watanabe S, Isomoto H, Yotsuyanagi H, Itoi T, Takehara T, Mochida S. Akuta N, et al. Among authors: ikejima k. J Gastroenterol. 2026 Jun;61(6):693-710. doi: 10.1007/s00535-026-02408-2. Epub 2026 May 13. J Gastroenterol. 2026. PMID: 42120590 Free PMC article. Review.
Fibroblast growth factor 18 stimulates the proliferation of hepatic stellate cells, thereby inducing liver fibrosis.
Tsuchiya Y, Seki T, Kobayashi K, Komazawa-Sakon S, Shichino S, Nishina T, Fukuhara K, Ikejima K, Nagai H, Igarashi Y, Ueha S, Oikawa A, Tsurusaki S, Yamazaki S, Nishiyama C, Mikami T, Yagita H, Okumura K, Kido T, Miyajima A, Matsushima K, Imasaka M, Araki K, Imamura T, Ohmuraya M, Tanaka M, Nakano H. Tsuchiya Y, et al. Among authors: ikejima k. Nat Commun. 2023 Oct 9;14(1):6304. doi: 10.1038/s41467-023-42058-z. Nat Commun. 2023. PMID: 37813881 Free PMC article.
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.
Akuta N, Kogiso T, Ikejima K, Otsuka M, Kawaguchi T, Kawanaka M, Takahashi H, Tamaki N, Nakagawa H, Hikita H, Fujii H, Yamaguchi K, Yoneda M, Kon K, Uchiyama A, Seko Y, Sakane S, Shigefuku R, Fujiwara N, Iwaki M, Kobayashi T, Adachi T, Takeuchi Y, Tsutsumi T, Nakano D, Shibayama K, Urata N, Miyaaki H, Kuroda H, Koseki M, Sone H, Matsubayashi Y, Kakisaka K, Takai A, Notsumata K, Seike M, Takei Y, Takeyama Y, Eguchi S, Watanabe S, Isomoto H, Yotsuyanagi H, Itoi T, Takehara T, Mochida S. Akuta N, et al. Among authors: ikejima k. Hepatol Res. 2026 Jun;56(6):887-902. doi: 10.1111/hepr.70188. Epub 2026 May 12. Hepatol Res. 2026. PMID: 42118685
Liver diseases and metabolic syndrome.
Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Watanabe S, et al. Among authors: ikejima k. J Gastroenterol. 2008;43(7):509-18. doi: 10.1007/s00535-008-2193-6. Epub 2008 Jul 23. J Gastroenterol. 2008. PMID: 18648737 Review.
[Pathophysiology of NASH].
Takei Y, Ikejima K, Sato N. Takei Y, et al. Among authors: ikejima k. Nihon Shokakibyo Gakkai Zasshi. 2004 Nov;101(11):1194-203. Nihon Shokakibyo Gakkai Zasshi. 2004. PMID: 15570867 Review. Japanese. No abstract available.
Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.
Fukada H, Kon K, Yaginuma R, Uchiyama A, Morinaga M, Ishizuka K, Fukuhara K, Okubo H, Suzuki S, Nojiri S, Yamashina S, Ikejima K. Fukada H, et al. Among authors: ikejima k. Front Med (Lausanne). 2025 Mar 25;12:1542741. doi: 10.3389/fmed.2025.1542741. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40201320 Free PMC article.
119 results